390 related articles for article (PubMed ID: 23043158)
1. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
Chen Y; Hu Y; Lin M; Jenkins AJ; Keech AC; Mott R; Lyons TJ; Ma JX
Diabetes; 2013 Jan; 62(1):261-72. PubMed ID: 23043158
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina.
Ding L; Cheng R; Hu Y; Takahashi Y; Jenkins AJ; Keech AC; Humphries KM; Gu X; Elliott MH; Xia X; Ma JX
Am J Pathol; 2014 Oct; 184(10):2709-20. PubMed ID: 25108226
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.
Qiu F; Matlock G; Chen Q; Zhou K; Du Y; Wang X; Ma JX
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5065-5075. PubMed ID: 28980001
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Role of
Chen Q; Qiu F; Zhou K; Matlock HG; Takahashi Y; Rajala RVS; Yang Y; Moran E; Ma JX
Diabetes; 2017 Jun; 66(6):1671-1682. PubMed ID: 28270521
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.
Hu Y; Chen Y; Ding L; He X; Takahashi Y; Gao Y; Shen W; Cheng R; Chen Q; Qi X; Boulton ME; Ma JX
Proc Natl Acad Sci U S A; 2013 Sep; 110(38):15401-6. PubMed ID: 24003152
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
Pearsall EA; Cheng R; Matsuzaki S; Zhou K; Ding L; Ahn B; Kinter M; Humphries KM; Quiambao AB; Farjo RA; Ma JX
PLoS One; 2019; 14(2):e0208399. PubMed ID: 30716067
[TBL] [Abstract][Full Text] [Related]
9. Protective and antioxidant effects of PPARα in the ischemic retina.
Moran E; Ding L; Wang Z; Cheng R; Chen Q; Moore R; Takahashi Y; Ma JX
Invest Ophthalmol Vis Sci; 2014 May; 55(7):4568-76. PubMed ID: 24825105
[TBL] [Abstract][Full Text] [Related]
10. PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.
Wang Z; Moran E; Ding L; Cheng R; Xu X; Ma JX
Invest Ophthalmol Vis Sci; 2014 May; 55(6):3820-32. PubMed ID: 24845641
[TBL] [Abstract][Full Text] [Related]
11. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
Abcouwer SF
Diabetes; 2013 Jan; 62(1):36-8. PubMed ID: 23258912
[No Abstract] [Full Text] [Related]
12. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation.
Liu Q; Zhang X; Cheng R; Ma JX; Yi J; Li J
Cell Tissue Res; 2019 May; 376(2):165-177. PubMed ID: 30610453
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.
Liu Q; Zhang F; Zhang X; Cheng R; Ma JX; Yi J; Li J
Mol Cell Biochem; 2018 Aug; 445(1-2):105-115. PubMed ID: 29264825
[TBL] [Abstract][Full Text] [Related]
14. A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism.
Shao Y; Chen J; Dong LJ; He X; Cheng R; Zhou K; Liu J; Qiu F; Li XR; Ma JX
Diabetes; 2019 Nov; 68(11):2131-2142. PubMed ID: 31451517
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway.
Dong L; Cheng R; Ma X; Liang W; Hong Y; Li H; Zhou K; Du Y; Takahashi Y; Zhang X; Li XR; Ma JX
Diabetes; 2023 Jul; 72(7):958-972. PubMed ID: 37058417
[TBL] [Abstract][Full Text] [Related]
16. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
17. Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
Joharapurkar A; Patel V; Kshirsagar S; Patel MS; Savsani H; Jain M
Eur J Pharmacol; 2021 May; 899():174032. PubMed ID: 33753107
[TBL] [Abstract][Full Text] [Related]
18. Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model.
Yeh PT; Wang LC; Chang SW; Yang WS; Yang CM; Yang CH
Curr Eye Res; 2019 Oct; 44(10):1121-1132. PubMed ID: 31109206
[No Abstract] [Full Text] [Related]
19. Anti-inflammatory and antioxidant effects of SERPINA3K in the retina.
Zhang B; Hu Y; Ma JX
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3943-52. PubMed ID: 19324842
[TBL] [Abstract][Full Text] [Related]
20. PPARα activation directly upregulates thrombomodulin in the diabetic retina.
Shiono A; Sasaki H; Sekine R; Abe Y; Matsumura Y; Inagaki T; Tanaka T; Kodama T; Aburatani H; Sakai J; Takagi H
Sci Rep; 2020 Jul; 10(1):10837. PubMed ID: 32616724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
